Sarepta Therapeutics, Inc.
EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
Last updated:
Abstract:
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
Status:
Application
Type:
Utility
Filling date:
30 May 2018
Issue date:
5 Dec 2019